Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients

详细信息    查看全文

• 作者：C. Benitez-Buelga ; L. Sanchez-Barroso ; M. Gallardo…
• 关键词：Chemotherapy ; Sporadic breast cancer ; Familial breast cancer ; Telomere length ; Telomerase
• 刊名：Breast Cancer Research and Treatment
• 出版年：2015
• 出版时间：January 2015
• 年：2015
• 卷：149
• 期：2
• 页码：385-394
• 全文大小：910 KB
• 参考文献：1. Blackburn EH (2001) Switching and signaling at the telomere. Cell 106(6):661-73 CrossRef
  2. Blasco MA (2005) Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 6(8):611-22 CrossRef
  3. Muezzinler A, Zaineddin AK, Brenner H (2013) A systematic review of leukocyte telomere length and age in adults. Ageing Res Rev 12(2):509-19 CrossRef
  4. Harley CB, Futcher AB, Greider CW (1990) Telomeres shorten during ageing of human fibroblasts. Nature 345(6274):458-60 CrossRef
  5. Kong CM, Lee XW, Wang X (2013) Telomere shortening in human diseases. FEBS J 280(14):3180-193 CrossRef
  6. Wentzensen IM, Mirabello L, Pfeiffer RM, Savage SA (2011) The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomark Prev 20(6):1238-250 CrossRef
  7. Fyhrquist F, Silventoinen K, Saijonmaa O et al (2011) Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hum Hypertens 25(12):711-18 CrossRef
  8. Willeit P, Willeit J, Kloss-Brandstatter A, Kronenberg F, Kiechl S (2011) Fifteen-year follow-up of association between telomere length and incident cancer and cancer mortality. JAMA 306(1):42-4 CrossRef
  9. Willeit P, Willeit J, Mayr A et al (2010) Telomere length and risk of incident cancer and cancer mortality. JAMA 304(1):69-5 CrossRef
  10. Shao L, Wood CG, Zhang D et al (2007) Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol 178(4 Pt 1):1492-496 CrossRef
  11. Wu X, Amos CI, Zhu Y et al (2003) Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 95(16):1211-218 CrossRef
  12. Weischer M, Nordestgaard BG, Cawthon RM, Freiberg JJ, Tybjaerg-Hansen A, Bojesen SE (2013) Short telomere length, cancer survival, and cancer risk in 47102 individuals. J Natl Cancer Inst 105(7):459-68 CrossRef
  13. Savage SA, Gadalla SM, Chanock SJ (2013) The long and short of telomeres and cancer association studies. J Natl Cancer Inst 105(7):448-49 CrossRef
  14. Cunningham JM, Johnson RA, Litzelman K et al (2013) Telomere length varies by DNA extraction method: implications for epidemiologic research. Cancer Epidemiol Biomark Prev 22(11):2047-054 CrossRef
  15. Aviv A, Hunt SC, Lin J, Cao X, Kimura M, Blackburn E (2011) Impartial comparative analysis of measurement of leukocyte telomere length/DNA content by Southern blots and qPCR. Nucleic Acids Res 39(20):e134 CrossRef
  16. Aviv A, Valdes AM, Spector TD (2006) Human telomere biology: pitfalls of moving from the laboratory to epidemiology. Int J Epidemiol 35(6):1424-429 CrossRef
  17. Martinez-Delgado B, Yanowsky K, Inglada-Perez L et al (2011) Genetic anticipation is associated with telomere shortening in hereditary breast cancer. PLoS Genet 7(7):e1002182 CrossRef
  18. Pooley KA, McGuffog L, Barrowdale D et al (2014) Lymphocyte telomere length is longer in
• 作者单位：C. Benitez-Buelga (1)
  L. Sanchez-Barroso (2)
  M. Gallardo (3)
  María Apellániz-Ruiz (2)
  L. Inglada-Pérez (2) (4)
  K. Yanowski (1)
  J. Carrillo (4) (5)
  L. Garcia-Estevez (6)
  I. Calvo (7)
  R. Perona (4) (5)
  M. Urioste (4) (8)
  A. Osorio (1) (4)
  M. A. Blasco (3)
  C. Rodriguez-Antona (2) (4)
  J. Benitez (1) (4)
  
  1. Human Genetics Group, Spanish National Cancer Research Center (CNIO), 28029, Madrid, Spain
  2. Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), 28029, Madrid, Spain
  3. Telomere and Telomerase Group, Spanish National Cancer Research Center (CNIO), 28029, Madrid, Spain
  4. Center for Biomedical Network Research on Rare Diseases (CIBERER), CNIO, 28029, Madrid, Spain
  5. Biomedical Research Institute Alberto Sols (CSIC-UAM), 28029, Madrid, Spain
  6. Medical Oncology Dptm., Centro Integral Oncológico Clara Campal, Madrid, Spain
  7. Medical Oncology Dptm., Hospital Montepríncipe, Madrid, Spain
  8. Familial Cancer Unit, Spanish National Cancer Research Center (CNIO), 28029, Madrid, Spain
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  
• 出版者：Springer Netherlands
• ISSN：1573-7217

文摘

Recently, we observed that telomeres of BRCA1/2 mutation carriers were shorter than those of controls or sporadic breast cancer patients, suggesting that mutations in these genes might be responsible for this event. Given the contradictory results reported in the literature, we tested whether other parameters, such as chemotherapy, could be modifying telomere length (TL). We performed a cross-sectional study measuring leukocyte TL of 266 sporadic breasts cancer patients treated with first-line chemotherapy, with a median follow-up of 240?days. Additionally, we performed both cross-sectional and longitudinal studies in a series of 236 familial breast cancer patients that included affected and non-affected BRCA1/2 mutation carriers. We have measured in leukocytes from peripheral blood: the TL, percentage of short telomeres (